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EGFR Inhibitor as Second-Line 
Therapy in a Patient With Mutant 
RAS Metastatic Colorectal Cancer: 
Circulating Tumor DNA to 
Personalize Treatment
INTRODUCTION
RAS mutations are found in 30% to 50% of met-
astatic colorectal cancer (mCRC) and determine 
the ineligibility of patients for epidermal growth 
factor receptor (EGFR)–targeted therapies. 
RAS mutations are associated with inferior 
progression-free survival and overall survival of 
patients with mCRC compared with patients with 
nonmutated tumors.1 It is conceivable that RAS 
mutations are negative prognostic factors per se; 
however, the availability of only one actionable 
molecular target, that is, the inhibition of angio-
genesis, in patients with mutated tumors cer-
tainly affects survival in this subgroup of patients. 
Therefore, genotyping colorectal cancer tissue 
is mandatory in routine practice to personalize 
the therapeutic approach. Recent studies have 
demonstrated that the analysis of circulating 
tumor DNA (ctDNA) in blood samples, through 
its ability to recapitulate tumor heterogeneity, 
is a remarkable surrogate of tumor biopsy for 
mutation detection.2 Extensive research on liq-
uid biopsy led to significant achievements in the 
comprehension of the biologic reasons behind 
acquired resistance to anti-EGFR therapies.3 
To date, studies with liquid biopsy have been 
selectively concentrated on the appearance of 
RAS-mutant clones in the blood of patients with 
RAS wild-type primary CRC, as biomarkers of 
anti-EGFR therapy resistance. Conversely, the 
clinical implications of the selective pressure 
exerted by antiangiogenic treatments in patients 
with RAS-mutant CRC have been seldom inves-
tigated. We here report that ctDNA analysis, 
over the course of antiangiogenic treatment, 
might reveal a therapeutically exploitable win-
dow of opportunity, characterized by the relative 
prevalence of RAS wild-type clones over time. As 
proof of concept, we here describe the case of a 
patient with a primary NRAS–mutated colorec-
tal cancer, who received second-line treatment 
with anti-EGFR after failure of first-line triplet 
chemotherapy plus bevacizumab, according to 
the absence of any clinically relevant mutation of 
RAS genes in blood, achieving a partial response.
CASE REPORT
A 47-year-old male patient presented in March 
2016 to our unit with a palpable painless left 
supraclavicular mass. A whole-body contrast- 
enhanced computed tomography (CT) scan 
revealed a left supraclavicular lymphadenop-
athy, transverse colon thickening (3 cm), mul-
tiple chest and abdominal lymphadenopathies, 
and peritoneal carcinomatosis. Colonoscopy 
revealed a bleeding area at 15 cm from the anal 
verge; biopsy was performed, and the result was 
negative for a primary cancer. Supraclavicular 
lymph node excision revealed a papillary adeno-
carcinoma, with immunohistochemistry positive 
for CDK20 and CDX2 and negative for TTF1 
and CK7. Mutational analysis of the lymph node 
metastasis performed through real-time poly-
merase chain reaction (PCR; Real-time Onco-
Screen NRAS) revealed exon 4 NRAS A146T 
mutation at 29 cycles. A whole-body fluorode-
oxyglucose positron emission tomography scan 
revealed several metabolically active lymph 
nodes (standardized uptake value [SUV], 1.7 
to 4.5) and a focal uptake in the rectosigmoid 
junction (SUV, 5). Given the intestinal immu-
nohistochemistry profile, he was started on a 
colon-specific regimen, with combined triplet 
chemotherapy of fluoropyrimidines, oxaliplatin, 
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and irinotecan plus an anti-VEGF monoclonal 
antibody (April to August 2016). Serum tumor 
markers significantly decreased, with rapid neg-
ativization (carcinoembryonic antigen [CEA], 
1.3→1.23; CA 19-9, 71.8→39; CA-125, 82→26). 
After eight cycles of therapy, fluorodeoxyglu-
cose positron emission tomography scan showed 
a partial response. From September 2016 to 
October 2016, the patient received fluoroura-
cil plus bevacizumab maintenance chemother-
apy. After 2 months of therapy, serum levels 
of CA 19-9 started increasing again (131), and 
irinotecan was reintroduced together with flu-
orouracil and bevacizumab. Clinical and radio-
logic reassessment revealed stable disease until 
June 2017. At that time, serum tumor markers 
increased again (CA 19-9, 530; CEA, 9), with 
clinical evidence of bilateral axillary lymph node 
enlargement. A whole-body CT scan confirmed 
the progression of disease, revealing pleural 
effusion associated with pulmonary lymphan-
gitic carcinomatosis. Concurrently, the patient 
was enrolled in an observational study open at 
our institution, which aimed to serially monitor 
the mutational status of ctDNA in patients with 
RAS-mutant mCRC disease, before starting any 
new line of treatment and in course of therapy 
until progression.
METHODS
 
Blood samples were prospectively collected 
after obtaining informed consent with ethical 
committee approval. Blood draws (8 mL) were 
performed starting from the failure of first-line 
therapy and serially repeated every 3 months 
until December 2017. Idylla (Biocartis, NV, 
Mechelen, Belgium), a fully automated, real-
time PCR-based molecular diagnostics system, 
was used to investigate RAS mutational profile 
from plasma. Specifically, Idylla ctKRAS Muta-
tion Assay and Idylla ctNRAS/BRAF/EGFR 
Mutation Assay were used. The first allows the 
detection of 21 mutations in codons 12, 13, 59, 
61, 117, and 146 of the KRAS gene, and the 
second allows the detection of 18 mutations in 
codons 12, 13, 59, 61, 117, and 146 of the NRAS 
gene, five mutations in codon 600 of the BRAF 
gene, and two mutations in codon 492 of the 
EGFR gene from 1 mL of plasma.
Among the parameters describing the generated 
PCR curves, the ΔCq value is calculated as the 
difference between the quantification cycle value 
(Cq) of the gene control signal and the Cq of 
the mutant signal. A sample is classified as muta-
tion positive if the parameters of the PCR curve 
generated are within the validated range. Oth-
erwise the sample is reported as being mutation 
negative, that is, wild type. According to the 
manufacturer's instructions, a Cq value of the 
NRAS control of 35.5 or higher indicates that 
a low amount of cell-free DNA is present in the 
sample. In such cases, low-frequency mutations 
may not be detected.
RESULTS
In July 2017, a ctDNA mutational analysis was 
performed and revealed the absence of any clin-
ically relevant mutation in KRAS, NRAS, and 
BRAF genes. The Cq of NRAS total was 28, 
to indicate that input was sufficient. This new 
insight into the biology of the disease convinced 
us to take this window of therapeutic opportu-
nity, which was not guaranteed to remain open 
indefinitely; in July 2017, the treatment was 
changed to the second-line combination of irino-
tecan and cetuximab. As early as after the first 
cycle of chemotherapy, an objective complete 
clinical response of the bilateral axillary adenop-
athy was documented, and this was confirmed at 
ultrasound assessment. Restaging CT scan after 
eight cycles of therapy showed a partial response, 
with significant reduction of pleural effusion and 
pulmonary lymphangitic carcinomatosis and sta-
bility of peritoneal metastases (Fig 1). A second 
ctDNA analysis was performed on November 
2017, confirming the RAS genes wild-type sta-
tus (Cq of NRAS total: 35.5, which might be due 
to a reduction in ctDNA amount). Accordingly, 
the patient continues to receive fluorouracil, 
leucovorin, and irinotecan plus cetuximab with 
the same schedule. The patient’s therapeutic his-
tory is illustrated in Figure 2. Unpublished pre-
liminary results, obtained in a series of patients 
with mCRC treated at our institution and seri-
ally monitored through plasma ctDNA analy-
sis, show that 46% of patients harboring a RAS 
mutation in tumor tissue at the time of diagnosis 
switch to a nonmutated/wild-type RAS status 
during the course of chemotherapy plus antian-
giogenic drugs (Table 1).
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June 2017
(before FOLFIRI-cetuximab) 
October 2017
(after 3 months of FOLFIRI-cetuximab) 
Pleural effusion 
Pulmonary lymphangitic
carcinomatosis 
Malignant ascites 
Peritoneal carcinosis 
Fig 1. Axial computed tomography scan after eight cycles of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab shows a partial 
response, with significant reduction of pleural effusion and pulmonary lymphangitic carcinomatosis and stability of peritoneal metastases. Red 
arrows indicate target lesions.
Downloaded from ascopubs.org by 79.36.48.20 on July 2, 2019 from 079.036.048.020
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
DISCUSSION
It is recognized that the NRAS A146T muta-
tion that we found in tumor tissue at the time 
of diagnosis is rare, with a reported preva-
lence of NRAS exon 4 mutations (c117 and 
c146) around 0.5% across studies. Neverthe-
less, A146T results in increased NRAS activity 
and downstream signaling and is transforming 
in cell culture resulting from increased NRAS 
guanosine diphosphate/guanosine triphosphate 
exchange rate,4 and consequently patients who 
harbor mutations in NRAS also have signifi-
cantly inferior anti-EGFR treatment outcomes 
benefit compared with those without any RAS 
mutations.5 It is recommended that patients with 
CRC being considered for anti-EGFR therapy 
must receive RAS mutational testing, including 
KRAS and NRAS codons 12 and 13 of exon 2, 
59, and 61 of exon 3 and 117 and 146 of exon 4, 
and that anti-EGFR should only be prescribed 
for patients with mCRC who are wild type for 
all known RAS-activating mutations.6 In patients 
with RAS-mutant primary colorectal cancers, 
ineligible for EGFR inhibitors, the importance 
of the EGFR pathway, which indeed sustains 
the disease, is counterintuitive. International 
guidelines currently recommend treatment of 
RAS mutant mCRC with bevacizumab first line, 
followed by chemotherapy backbone change 
or aflibercept/ramucirumab at disease progres-
sion.7 Preclinical and clinical data, however, 
demonstrate that tumor angiogenesis inhibition 
induces biologic changes in tumor-stroma inter-
actions, mainly derived from hypoxia. Preclin-
ical observations suggest that hypoxia exerts a 
negative selection against RAS-mutant clones 
through a mechanism known as secretory senes-
cence, in which RAS-mutant senescent cells 
operate in a paracrine manner to support the 
growth of surrounding RAS wild-type clones, 
leading to their relative prevalence over time.8 
We here report that ctDNA analysis, under 
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Fig 2. Diagnostic and 
therapeutic timeline.  
Sequence of treatments, 
clinical and radiologic 
response to the different 
schedules adopted (partial 
response [PR] is indicated by 
blue arrow, and progressive 
disease [PD] is indicated by 
red arrow), and molecular  
tests performed on tumor 
tissue and plasma at  
different time points. Bev,  
bevaci zumab; cet, cetuximab; 
ctDNA, circulating  
tumor DNA; FOLFIRI, 
fluoro uracil, leucovorin, and 
irinotecan; FOLFOXIRI, 
fluorouracil, leucovorin, 
oxaliplatin, and irinotecan; 
FU, fluorouracil. 
Table 1. Patients With RAS-Mutated Metastatic Colorectal Cancer Who Converted to a Nonmutated/Wild-Type RAS Status in Plasma During 
the Course of Therapy Serially Monitored Through Circulating Tumor DNA Analysis
Patient ID
Tissue Point Mutation 
(baseline)
Plasma Point Mutation 
(baseline)
Plasma Point 
Mutation  
(2-3 months)
Plasma Point 
Mutation  
(4-6 months)
Plasma Point 
Mutation  
(6-8 months)
1 KRAS A146T KRAS A146T WT WT WT
2 KRAS Q61H KRAS Q61H KRAS Q61H WT *
3 KRAS G12C KRAS G12C WT WT WT
4 KRAS G12C KRAS G12C WT KRAS G12C KRAS G12C
5 KRAS G13D KRAS G13D KRAS G13D WT WT
6 KRAS G12V KRAS G12V WT WT WT
7 KRAS G12D KRAS G12D WT WT KRAS G12C
Abbreviation: WT, wild type.
*Death.
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antiangiogenic treatment, might reveal a ther-
apeutically exploitable window of opportunity, 
characterized by the relative prevalence of RAS 
wild-type clones, which can be converted in a 
clinically meaningful benefit for patients. Tar-
geting this window with EGFR inhibitors might 
represent an exploitable second-line option in 
RAS-mutant CRC. To date, the adaptation of a 
RAS-mutant colorectal cancer genome to angio-
genesis inhibition has never been exploited for 
therapeutic purpose. Our planned KAIROS trial 
(Keeping the Advantage of the Impermanent 
ascopubs.org/journal/po JCO™ Precision Oncology 5
RAS–Wild Type Window Offering Second-Line 
EGFR Inhibitors) is expected to help determine 
whether the response to EGFR inhibition, in 
patients with RAS-mutant primary cancers con-
verted to RAS wild type in the course of first-line 
antiangiogenic treatments, might become the 
rule rather than the exception.
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